| Market Cap | 2.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -546.25K |
| Shares Out | n/a |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,500 |
| Average Volume | 13,922 |
| Open | 0.0299 |
| Previous Close | 0.0330 |
| Day's Range | 0.0299 - 0.0299 |
| 52-Week Range | 0.0058 - 0.0330 |
| Beta | -1.97 |
| RSI | 49.97 |
| Earnings Date | Aug 27, 2025 |
About Diagnamed Holdings
Diagnamed Holdings Corp. engages in the development and commercialization of AI healthcare solutions. It focuses on developing BRAIN AGE BRAIN HEALTH, a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders; and CERVAI, brain health and wellness AI solution. It has a collaboration agreement with EIREX for the development and commercialization of EIREX’s novel modular carbon-free technology that extracts hydrogen from water. Diagnamed Holdi... [Read more]
News
DiagnaMed Acquires Strategic Ontario Claims Adjacent to QIMC in Premier Temiscamingue Hydrogen District
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a Canadian technology innovator specializing in advanced hydrogen extracti...
DiagnaMed Announces Closing of LIFE Offering
Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed" or the "Company"), a leading provider of cutting-edge technology solutions for th...
Revive Therapeutics Announces LOI to Acquire DiagnaMed's Molecular Hydrogen Program
TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- TORONTO, March 3, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company f...
DiagnaMed Announces LIFE Offering of up to $510,000
Toronto, Ontario--(Newsfile Corp. - February 27, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed" or the "Company"), a leading provider of cutting-edge technology solutions fo...
DiagnaMed To Support Quebec's Hydrogen Ambitions Through its Collaboration with QIMC
Toronto, Ontario--(Newsfile Corp. - February 27, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed", "DMED", or the "Company"), a leading provider of cutting-edge technology solu...
DiagnaMed Advances Hydrogen Energy Technology Innovation
TORONTO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed”, “DMED”, or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a leading provider of cutting-edge technology solutions for the ...
DiagnaMed and TerraVent Announce Strategic Collaboration for Next-Generation Clean Hydrogen Production
TORONTO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a leading provider of innovative technology solutions for the cleantech a...
DiagnaMed Announces Resignation of Director and Grant of Stock Options
TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF) announces that Elyssia Patterson has resigned from the board. The Company ...
QIMC and DiagnaMed to Advance Hydrogen Production Technology at the Ville Marie Clean Natural Renewable Hydrogen Project
A Strategic collaboration to Accelerate Clean Natural Hydrogen Innovation Lachute, Quebec--(Newsfile Corp. - January 8, 2025) - Québec Innovative Materials Corp. (CSE: QIMC) (FSE: 7FJ) (OTCQB: QIMCF) ...
DiagnaMed Partners with Texas Tech University to Pioneer Hydrogen Innovation
TORONTO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a leading innovator in hydrogen-producing technologies and artificial int...
DiagnaMed Announces Stock Option Grants and Shares for Debt Settlement
TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on molecular hydrogen and AI diagnostics,...
DiagnaMed Files U.S. Patent Application for Novel Methods of Producing Molecular Hydrogen
Advancing molecular hydrogen for neurological and mental health disorders Expects its molecular hydrogen product to be ready for use in December 2024 TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- DiagnaM...
DiagnaMed Advancing the Medical Potential of Hydrogen
TORONTO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on brain health, announces its strategic ...
DiagnaMed Expands with Drug and Clinical Research AI Platform
Leveraging proprietary EEG data from previous and future research studies with BRAIN AGE® Brain Health AI Accelerating clinical trial development and discovering potential novel treatments for neurolo...
DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is offe...
DiagnaMed Cancels Previously Announced Private Placement
TORONTO, July 03, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, announc...
DiagnaMed Announces LIFE Offering of up to $650,000
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is pleas...
DiagnaMed Announces Canadian Launch of BRAIN AGE® Brain Health AI
Clinics can apply at BrainAge.ca
DiagnaMed Adds New Launch Site of CERVAI™ Brain Health AI
TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), an artificial intelligence digital healthcare company, today announced i...
DiagnaMed Strengthening Intellectual Property Support for CERVAI™ Brain Health AI Solution
Potential $150,000 in non-dilutive funding support through IPON and IP Assist Programs Potential $150,000 in non-dilutive funding support through IPON and IP Assist Programs
DiagnaMed Announces Test Launch of CERVAI™ Brain Health in University Brain Health Center
TORONTO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a digital health artificial intelligence company focused on brain health,...
DiagnaMed Announces Pilot Launch of CERVAI™ Brain Health AI Solution
TORONTO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a digital health artificial intelligence company focused on brain health,...
DiagnaMed Accelerates Commercialization of CERVAI™ Brain Health AI Platform with Acceptance into the SOPHIE Program
TORONTO, Nov. 15, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a generative artificial intelligence healthcare company, is pleased to an...
DiagnaMed Launches New Healthcare Provider Network Program for CERVAI™ Brain Health AI Platform in Canada and the USA
Program provides healthcare providers access to Diagnamed's novel brain health AI platform Program provides healthcare providers access to Diagnamed's novel brain health AI platform
DiagnaMed Provides Update for its Brain Health AI Platform, CERVAI™
TORONTO, Sept. 13, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a generative artificial intelligence healthcare company, provides a deve...